The past several months have witnessed the emergence of SARS-CoV-2 variants with novel
spike protein mutations that are influencing the epidemiological and clinical aspects of the …

SUMMARY The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
respiratory disease coronavirus 2 (SARS-CoV-2), has led to millions of confirmed cases and …

The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear.
Although most randomized controlled trials have shown negative results, uncontrolled …

In December 2019, the novel betacoronavirus Severe Acute Respiratory Disease
Coronavirus 2 (SARS-CoV-2) was first detected in Wuhan, China. SARS-CoV-2 has since …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
stresses the continued need for next-generation vaccines that confer broad protection …

There is intense interest in antibody immunity to coronaviruses. However, it is unknown if
coronaviruses evolve to escape such immunity, and if so, how rapidly. Here we address this …

Reliable quantification of the antibody response to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) is highly relevant, eg, for identifying possible vaccine failure …

Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is
available as soon as there are survivors. The COVID-19 pandemic represented the first …

As novel SARS-CoV-2 variants with different patterns of spike protein mutations have
emerged, the susceptibility of these variants to neutralization by antibodies has been rapidly …

SARS-CoV-2 mRNA vaccines have demonstrated high efficacy and immunogenicity, but
limited information is currently available on memory B cell generation and long-term …